Ministry of Health and Long-Term Care Ontario Public Drug Programs. 1. What changes are occurring to the ONPP?

Similar documents
1. When are dispensers able to provide publicly funded naloxone emergency kits for Ontarians?

For the 2017/2018 Influenza Immunization Season. Patient Eligibility. Description. Ontario Public Drug Programs, Ministry of Health and Long-Term Care

Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch

Ontario Public Drug Programs, Ministry of Health and Long-Term Care. For the Influenza Immunization Season

This Frequently Asked Questions document contains various aspects of UIIP in the following sections. Overview Eligibility...

Overview. Ontario Public Drug Programs, Ministry of Health and Long-Term Care

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

Chronic Hepatitis B Drug Therapies: Frequently Asked Questions

Harm Reduction Program Enhancement Questions and Answers. Population and Public Health Division Ministry of Health and Long-Term Care

Community Pharmacy Distribution of Naloxone

Opioids - Fentanyl - Naloxone. Public Health Nurse

Administration of Publicly-Funded Influenza Vaccine by Pharmacists for Influenza Season

Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative

Erelzi (etanercept) Frequently Asked Questions

Influenza Immunization Drug Cards. Ontario 2018/19

MINISTRY OF HEALTH AND LONG-TERM CARE Primary Health Care Team FACT SHEET. New and Enhanced Incentives for Colorectal Cancer Screening

Influenza Immunization Drug Cards. Ontario (2017/18)

Ontario Public Drug Programs

MINISTRY REPONSE TO THE ONTARIO CITIZENS COUNCIL REPORT: INFORMING THE DEVELOPMENT OF A NEW DRUG PROGRAM IN ONTARIO

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no

Narcotics Monitoring System (NMS) Update

Frequently Asked Questions for Ontario Pharmacists: Blood Glucose Test Strip Reimbursement Policy

Appendix 1: Frequently Asked Questions

Medical Directive. Medical Director: Date Revised: January 1, Executive Director: Date Revised: January 1, 2019

NALOXONE RISK ASSESSMENT

TITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT

Protocol For: Personally Furnishing Naloxone. Update Log

Ontario s Narcotics Strategy

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS)

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions

Commercial & MassHealth Flu Reimbursement Program

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Influenza Immunization Drug Cards

Documenting Patient Immunization. Ontario 2018/19

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Naloxone Information for Community Pharmacies in Georgia: What You Need to Know

HUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012

Revised 16 February, of 7

Saving lives: Australian naloxone access model

Practice Direction Standard of Practice # 5: Administration of Drugs including Vaccines

ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health

REPORT Meeting Date: July 4, 2013 Regional Council

MedsCheck Reviews. Ontario

POWER TO HELP REVERSE AN OPIOID OVERDOSE

Inflectra Frequently Asked Questions

1. Introduction. Page 1. Preparation for the Influenza Season:

A Step-by-Step Guide for Rubicon Pharmacists Delivering the RubiReview Program (SMAP)

This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are:

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

Opioid Harm Reduction

Peer Naloxone. A harm reduction approach to overdose prevention. Kristel Guthrie RN BScN BA. Chantel Marshall RN BScN. The Works Toronto Public Health

There are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014

Request for Proposal. PA ACT 139 Naloxone Purchase

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

Prescription Opioid Overdose in Oregon: A public health perspective

A Bulletin for PHARMACY Service Providers from Alberta Blue Cross. Alberta Public Health Activities Program (APHAP)

Updates on take-home naloxone in France Anne-Claire BRISACIER OFDT

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals

SHOTS ADDING VFC VACCINES

COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO

Independent Dental Hygienists under the Non-Insured Health Benefits (NIHB) Program. Questions and Answers

Cancer Care Ontario / Ontario Public Drug Programs

MARYLAND BOARD OF PHARMACY

Ontario Drug Benefit Formulary/Comparative Drug Index

Opioid and Other Substance Misuse

Medicare Part D Overutilization Monitoring System

Presentation Objectives

Medicaid and the Opioid Crisis

Anyone Can Become Addicted. Anyone.

Section: Claims Payment - Cognitive Services (PAS Policy Administered by Drug Plan and Extended Benefits Branch)

The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded

Questions and Answers on 2009 H1N1 Vaccine Financing

Pharmacy Needle and Syringe Programme. Enhanced Contract

Medicare Part D Opioid Policies for 2019 Information for Patients

NALOXONE LEARNING ABOUT NALOXONE COULD SAVE A LIFE

ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE

Naloxone (Narcan) Initiatives and the Court System

Naloxone and Combating the Opioid Epidemic

Sample Managed Care Organization Survey Questions to Assess Smoking Prevalence and Available Cessation Benefits

Role of the Pharmacist: Naloxone Training. Kathleen Besinque, Pharm.D.,MSEd., FASHP, FCPhA Loma Linda University School of Pharmacy

LOUISIANA MEDICAID PROGRAM ISSUED: 02/01/12 REPLACED: 02/01/94 CHAPTER 5: PROFESSIONAL SERVICES SECTION 5.1: COVERED SERVICES PAGE(S) 5

Drug Overdose Prevention Program (DOPP)

Naloxone Non-Patient Specific Prescription and Pharmacist Dispensing Protocol, New York City

Frequent Dispensing Frequently Asked Questions

Sub. S.B. 119 As Passed by the Senate

Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario. Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012

COMBATING THE OPIATE CRISIS IN OHIO THROUGH COMPREHENSIVE RESPONSE 2018 HOUSING OHIO CONFERENCE APRIL 9 TH, Objectives: Key Terms

ADMINISTRATION OF NALOXONE HCI REVISED: 10/17

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Vaccine Starter Kit Program FAQs

Anthem Extras Packages for Seniors

Influenza Immunization Drug Cards. New Brunswick (2017/18)

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

STATE OF NEVADA DIVISION OF PUBLIC & BEHAVIORAL HEALTH

PROPOSED AMENDMENTS TO HOUSE BILL 3440

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

Pennsylvania DEPARTMENT OF HEALTH

Transcription:

Funding of Naloxone Nasal Spray Kits through the Ontario Naloxone Program for Pharmacies (ONPP) and Updates to the Existing Program: Frequently Asked Questions for Pharmacists 1. What changes are occurring to the ONPP? Effective March 27, 2018, funding of intranasal naloxone nasal spray (INNS) (Narcan Nasal Spray) kits will be added to the ONPP. Funding of injectable naloxone kits through the ONPP will remain unchanged. Eligible recipients will have the choice between injectable naloxone and INNS kits. Also, effective March 27, 2018, in limited circumstances, pharmacists may now: Provide naloxone kits to Ontarians who do not have an Ontario health card or to those who do not wish to provide identification; and Provide two naloxone kits to an eligible recipient at one time. 2. What are the contents of the INNS kit? Each INNS kit must contain the following: One hard case (preferred zippered hard black case with red naloxone cross); Two doses 4mg/0.1 ml naloxone hydrochloride intra-nasal spray; One pair of non-latex gloves; One naloxone identifier card; and One insert with additional information on the medication (both in English and French). 3. Does the ministry provide pre-made kits? No, the ministry does not provide pre-made kits. Pharmacists may obtain pre-made kits through their suppliers or obtain individual supplies to create their own kit. 1

For more information please refer to the Ontario Pharmacists Association website at: https://www.opatoday.com/professional/naloxone_kit_tools 4. Are all Ontarians eligible to receive publicly funded intra-nasal kits? Yes, as of March 27, 2018, eligible persons are able to receive INNS kits for participating pharmacies at no cost. Criteria for eligible persons include: A person who is either currently using opioids or is a past opioid user who is at risk of returning to opioid use, or A family member, friend or other person in a position to assist a person at risk of overdose from opioids. 5. Who decides which naloxone kit will be distributed to eligible recipients? Eligible recipients will have the choice between obtaining INNs or injectable naloxone from their pharmacist. 6. Can an eligible recipient receive both an intra-nasal naloxone spray and an injectable naloxone kit? Eligible recipients can receive both an intra-nasal naloxone spray and an injectable naloxone kit if both are requested. 7. How much will the pharmacy be reimbursed for providing the INNS kits? The total amount reimbursed by the government when providing the intra-nasal naloxone kit is $120.00. This amount includes the naloxone kit at $110.00 (drug cost and mark-up included) and a professional fee of $10.00. There are no additional training fees for the INNS kits. 8. Why are there no additional training fees for the intra-nasal naloxone kits? 2

INNS does not require any special instructions to administer and as such, the need for specific training is not necessary. Pharmacists should provide guidance to individuals who obtain a kit on who to administer the intra-nasal spray as they would for any other prescription intra-nasal drug. The intra-nasal device used in the product is very similar to devices used with other medications and requires no specialized training. 9. How do pharmacies bill the Health Network System (HNS) for reimbursement for naloxone products? Table 1: PINs to support reimbursement of Naloxone Kits PIN 93877255 Description Intra-Nasal Naloxone Kit $110 naloxone kit Dosage Form Total Amount Reimbursed Intra-Nasal $120.00 Initial Injectable Naloxone Kit $35 naloxone kit 93877251 $25 training fee Injectable $70.00 93877252 93877256 Replacement Injectable Naloxone Kit initial kit with no training) $35 naloxone kit Two Intra-Nasal Naloxone Kits professional fee only) $220 two naloxone kits (one (or Injectable $45.00 Intra-Nasal $230.00 3

PIN Description Dosage Form Total Amount Reimbursed Two Injectable Naloxone Kits (one initial and one replacement kit with one professional fee only) 93877257 $70 two naloxone kits Injectable $105.00 $25 training fee Two Injectable Naloxone Kits (two replacement kits with one professional fee only) 93877258 $70 two naloxone kits Injectable $80.00 Claims must be submitted using the ministry-assigned PIN associated with the naloxone kit and service provided. Do not use the Drug Identification Number (DIN) of the naloxone that is contained in the naloxone kit. 10. How many naloxone kits can be provided to an eligible recipient at one-time? At this time, a maximum of two (2) naloxone kits may be provided to an eligible recipient at one time. 11. How do pharmacies bill the HNS for reimbursement for two naloxone kits? Pharmacies can provide eligible recipients up to two naloxone kits by submitting the appropriate PIN. When providing one injectable naloxone kit and one intra-nasal naloxone kit, pharmacies would submit two separate PINs as two separate claims to receive full reimbursement. 12. What is the procedure to submit the claim to the HNS for publicly funded intra-nasal naloxone kit for an Ontario Drug Benefit (ODB) eligible recipient? 4

The claim submission follows the normal process for submitting claims on the HNS with the following additional information: Intervention code PS : (Professional Care Service); Product Identification Number (PIN): see tables above for list of PINs; Valid Pharmacist ID; and Professional Fee: see table above for Total Amount Reimbursed for each kit. 13. How can an eligible recipient WITHOUT an Ontario health card number obtain a naloxone kit from a pharmacy? Reasonable efforts should be made to obtain a health card number when providing a naloxone kit. However, the ministry recognizes that some Ontarians may not have a valid OHIP card or may wish not to be identified when obtaining a naloxone kit from a pharmacy. Effective March 27, 2018, pharmacists may provide naloxone kits to eligible recipients who do not have an Ontario health card number or to those who do not wish to provide identification. Pharmacists should use their professional judgement and ensure proper documentation is maintained. Ontarians can also obtain a naloxone kit without a health card from community-based organizations such as needle syringe and Hepatitis C programs under the Ontario Naloxone Program (ONP). For a searchable list of locations where Ontarians can get a naloxone kit, please visit our searchable database. 14. How do I submit a claim on the HNS for non-odb eligible recipients WITHOUT an Ontario health card number? When submitting a claim for an eligible person who does not have ODB coverage, pharmacists must submit the following information: First Name: HARM Last Name: REDUCTION Person s Gender: F = female; M = male; (or) Blank 5

Person s Date of Birth: Valid YYYYMMDD (if known) or 20000101 Proxy patient ID: 89999 999 91 Intervention codes: PS (Professional Care Services) Product Identification Number (PIN) Valid Pharmacist ID Maximum Reimbursement Amount 15. Are the pharmacy record requirements the same for INNS and injectable naloxone? Standard record keeping requirements under current standards of practice apply. Pharmacies must keep a record when the naloxone kit is provided to the eligible recipient. Pharmacy records must be maintained in a readily available format for post-payment verification for a minimum of 2 years. 16. Are pharmacists required to track outcomes of the individuals who were provided a naloxone kit? Pharmacists, where possible, must ensure that a quarterly report (available at: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx), relating to outcomes for individuals who were provided a naloxone kit, be completed and returned to the ministry. The report schedule is as follows: Table 2: Quarterly Reporting Requirements for Providing Naloxone Quarter Report due date Q1 (April June) June 30 Q2 (July September) October 30 Q3 (October December) January 30 Q4 (January March) April 30 17. Can naloxone kits be provided for veterinary purposes? Naloxone is a Schedule II product and as such can be purchased for veterinary purposes at any pharmacy. Kits provided for veterinary purpose do not quality for public funding. 6

18. Where can I find additional information regarding the ministry s naloxone programs? For more information on the ministry s naloxone programs, please refer to the following websites: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx https://www.ontario.ca/page/get-naloxone-kits-free Additional Information: For pharmacies: Please call ODB Pharmacy Help Desk at: 1-800-668-6641 For all other Health Care Providers and the Public: Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282 7